Journal: Journal of Virology

Article Title: The subgenomic flaviviral RNA suppresses RNA interference through competing with siRNAs for binding RISC components

doi: 10.1128/jvi.01954-23

Figure Lengend Snippet: ZIKV sfRNA competes with siRNA for binding to RHA and PACT. (A) SDS-PAGE of purified recombinant RHA (tandem dsRBDs, 1–264aa) and PACT. (B) Increasing amounts of unlabeled ZIKV sfRNA [left panel: 0.5 (lane 3), 2 (lane 4), 9 (lane5), or 27 (lane 6) pmoles; right panel: 0.2 (lane 3), 0.5 (lane 4), 1 (lane5), or 3 (lane 6) pmoles] (B) or control RNA (C) were incubated with 4 µM protein and 10 nM biotin-labeled siRNA as indicated in a 20 μL reaction. Samples were separated on a 6% native-TBE polyacrylamide gel electrophoresis (PAGE), transferred to membranes, and then incubated with Horseradish-conjugated Streptavidin.

Article Snippet: Blots were developed using an enhanced chemiluminescence (ECL) kit. . Electrophoretic mobility shift assay The recombinant proteins His&SUMO-RHA(1–264aa) and His&GST-PACT were expressed and purified by Sino Biological Inc. (Beijing, China).

Techniques: Binding Assay, SDS Page, Purification, Recombinant, Incubation, Labeling, Polyacrylamide Gel Electrophoresis

Journal: Molecular biology of the cell

Article Title: Autocrine extracellular signal-regulated kinase (ERK) activation in normal human keratinocytes: metalloproteinase-mediated release of amphiregulin triggers signaling from ErbB1 to ERK.

doi: 10.1091/mbc.e04-03-0233

Figure Lengend Snippet: Figure 9. Stimulation of ERK phosphorylation by AR. NHKs were depleted of GFs in basal M154 medium for 48 h and then incubated for 20 min with fresh basal M154 containing 5 g/ml 225 IgG or 5 g/ml MOPC 21. Then, the indicated concentrations of AR or EGF were added, and incubation was continued for another 10 min. PBS was added rather than AR or EGF in the lane labeled 0. Nonionic detergent lysates were then prepared and subjected to western blotting (20 g protein/lane). Replicate blots were prepared and decorated with the antibodies indicated to the right of the autora- diographs. Arrowhead indicates mobility of ErbB1. For comparison with other figures, 0.17 nM EGF is 1 ng/ml. Note the decreased potency and effect of rhAR, compared with rhEGF.

Article Snippet: Recombinant human AR (rhAR) and neutralizing antibodies against TGF- , AR, HB-EGF, epiregulin, and betacellulin were from R&D Systems (Minneapolis, MN).

Techniques: Phospho-proteomics, Incubation, Labeling, Western Blot, Comparison

Journal: Clinical Drug Investigation

Article Title: Randomized Comparison Study of Novel Recombinant Human Antithrombin Gamma and Plasma-Derived Antithrombin in Healthy Volunteers

doi: 10.1007/s40261-019-00847-9

Figure Lengend Snippet: Time course of plasma antithrombin (AT) activity [linear plot; mean ± standard deviation (SD)] in subjects treated with three daily doses of 60 IU/kg of recombinant human antithrombin gamma (rhAT-gamma) ( n = 10) or 60 IU/kg of plasma-derived antithrombin (pAT) ( n = 10)

Article Snippet: Human recombinant antithrombin alfa (rhAT-alfa) [ATryn ® ; rEVO Biologics, Framingham, MA, USA] is a transgenic AT preparation purified from the milk of goats genetically engineered to produce human AT [ ].

Techniques: Clinical Proteomics, Activity Assay, Standard Deviation, Recombinant, Derivative Assay

Journal: Clinical Drug Investigation

Article Title: Randomized Comparison Study of Novel Recombinant Human Antithrombin Gamma and Plasma-Derived Antithrombin in Healthy Volunteers

doi: 10.1007/s40261-019-00847-9

Figure Lengend Snippet: Time course of plasma antithrombin (AT) antigen concentration [linear plot; mean ± standard deviation (SD)] in subjects treated with three daily doses of 60 IU/kg of recombinant human antithrombin gamma (rhAT-gamma) ( n = 10) or 60 IU/kg of plasma-derived antithrombin (pAT) ( n = 10)

Article Snippet: Human recombinant antithrombin alfa (rhAT-alfa) [ATryn ® ; rEVO Biologics, Framingham, MA, USA] is a transgenic AT preparation purified from the milk of goats genetically engineered to produce human AT [ ].

Techniques: Clinical Proteomics, Concentration Assay, Standard Deviation, Recombinant, Derivative Assay

Journal: Clinical Drug Investigation

Article Title: Randomized Comparison Study of Novel Recombinant Human Antithrombin Gamma and Plasma-Derived Antithrombin in Healthy Volunteers

doi: 10.1007/s40261-019-00847-9

Figure Lengend Snippet: Time course of plasma antithrombin (AT) antigen concentration [linear plot; mean ± standard deviation (SD)] in subjects treated with three daily doses of 72 IU/kg of recombinant human antithrombin gamma (rhAT-gamma) ( n = 21) or 60 IU/kg of plasma-derived antithrombin (pAT) ( n = 21)

Article Snippet: Human recombinant antithrombin alfa (rhAT-alfa) [ATryn ® ; rEVO Biologics, Framingham, MA, USA] is a transgenic AT preparation purified from the milk of goats genetically engineered to produce human AT [ ].

Techniques: Clinical Proteomics, Concentration Assay, Standard Deviation, Recombinant, Derivative Assay

Journal: Clinical Drug Investigation

Article Title: Randomized Comparison Study of Novel Recombinant Human Antithrombin Gamma and Plasma-Derived Antithrombin in Healthy Volunteers

doi: 10.1007/s40261-019-00847-9

Figure Lengend Snippet: Time course of plasma anti-Xa activity [linear plot; mean ± standard deviation (SD)] in subjects treated with three daily doses of 60 IU/kg of recombinant human antithrombin gamma (rhAT-gamma) ( n = 10) or 60 IU/kg of plasma-derived antithrombin (pAT) ( n = 10)

Article Snippet: Human recombinant antithrombin alfa (rhAT-alfa) [ATryn ® ; rEVO Biologics, Framingham, MA, USA] is a transgenic AT preparation purified from the milk of goats genetically engineered to produce human AT [ ].

Techniques: Clinical Proteomics, Activity Assay, Standard Deviation, Recombinant, Derivative Assay

Journal: Clinical Drug Investigation

Article Title: Randomized Comparison Study of Novel Recombinant Human Antithrombin Gamma and Plasma-Derived Antithrombin in Healthy Volunteers

doi: 10.1007/s40261-019-00847-9

Figure Lengend Snippet: Time course of plasma anti-Xa activity [linear plot; mean ± standard deviation (SD)] in subjects treated with three daily doses of 72 IU/kg of recombinant human antithrombin gamma (rhAT-gamma) ( n = 21) or 60 IU/kg of plasma-derived antithrombin (pAT) ( n = 21)

Article Snippet: Human recombinant antithrombin alfa (rhAT-alfa) [ATryn ® ; rEVO Biologics, Framingham, MA, USA] is a transgenic AT preparation purified from the milk of goats genetically engineered to produce human AT [ ].

Techniques: Clinical Proteomics, Activity Assay, Standard Deviation, Recombinant, Derivative Assay

Journal: Clinical Drug Investigation

Article Title: Randomized Comparison Study of Novel Recombinant Human Antithrombin Gamma and Plasma-Derived Antithrombin in Healthy Volunteers

doi: 10.1007/s40261-019-00847-9

Figure Lengend Snippet:

Article Snippet: Human recombinant antithrombin alfa (rhAT-alfa) [ATryn ® ; rEVO Biologics, Framingham, MA, USA] is a transgenic AT preparation purified from the milk of goats genetically engineered to produce human AT [ ].

Techniques: Recombinant, Clinical Proteomics, Coagulation